bluebird bio Inc (BLUE) was Reiterated by Maxim Group to “Buy” while Lowering the Price Target of the company shares to $ 85 from a previous price target of $105 . Maxim Group advised their investors in a research report released on Aug 4, 2016.
Many Wall Street Analysts have commented on bluebird bio Inc. bluebird bio Inc was Initiated by Cantor Fitzgerald to “Hold” on Jun 3, 2016.
On the company’s financial health, bluebird bio Inc reported $-1.59 EPS for the quarter, missing the analyst consensus estimate by $ -0.09 based on the information available during the earnings call on Aug 3, 2016. Analyst had a consensus of $-1.50. The company had revenue of $1.55 million for the quarter, compared to analysts expectations of $2.01 million. The company’s revenue was down -68.6 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-1.57 EPS.
bluebird bio Inc closed down -0.89 points or -1.58% at $55.41 with 8,66,788 shares getting traded on Tusday. Post opening the session at $56.03, the shares hit an intraday low of $53.27 and an intraday high of $56.67 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.
In a different news, on Jul 29, 2016, Eric Sullivan (Principal Accounting Officer) sold 2,912 shares at $55.01 per share price. According to the SEC, on Jul 19, 2016, David Davidson (Chief Medical Officer) sold 1,000 shares at $45.08 per share price. On Jun 16, 2016, Philip D Gregory (Chief Scientific Officer) sold 2,931 shares at $39.52 per share price, according to the Form-4 filing with the securities and exchange commission.
bluebird bio Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing products based on the transformative potential of gene therapy to treat patients with severe genetic diseases and cancer. The Company’s products include Lenti-D LentiGlobin and CAR T Cells. The Company is developing Lenti-D to treat patients with CCALD (Childhood cerebral adrenoleukodystrophy) the severe form of ALD (Adrenoleukodystrophy). The Company is conducting a Phase II/III clinical study of Lenti-D in the United States. The Company is developing LentiGlobin to treat patients with b-thalassemia and severe SCD (sickle cell disease). The Company is conducting a Phase I/II clinical study of LentiGlobin. It also initiated a second Phase I/II clinical study in the United States Australia and Thailand for LentiGlobin. The Company is developing CAR T cell technology to deliver T cells engineered to kill the cancer.